In November 2016, LIfeNet Health acquired the assets of Vivo Biosciences (VBI) is a biotechnology company developing âall-humanâ bioassay platforms for preclinical research, drug discovery and therapeutics. The company relies on its patented HuBiogel⢠technology, which emulates the biology of normal and disease tissues in vitro. A series of 3-D or Mini-tumor bioassay systems are developed for rapid analysis of drug efficacy, toxicity and therapy prediction, the major bottlenecks of current drug development pipelines. The 3D HuBiogel⢠Assay Platform is a novel in vitro assay platform that recapitulates human cells in a fully human extracellular matrix. These three dimensional systems provide the drug development industry with a cost efficient assay to identify drug efficacy and toxicity. SBIR involved at same location as Diversified Scientific and with a somewhat diffeence focus from the mid-nineties, shift to entirely NIH work c
